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Abstract
Given the scope of the human immunodeficiency virus (HIV) pandemic, millions of people will be
in need of chronic antiretroviral therapy (ART) for decades into the future. It is hoped that progress
in prevention of HIV infection can be made, but there have been few successes in this effort thus far.
At the same time, lifelong ART presents formidable problems. Therefore, while research must
continue on improvements in prevention and treatment, future HIV research should now also seek
to develop temporally contained therapies capable of eradicating HIV infection. This review will
explore what is known about the mechanisms that restrain HIV expression and result in persistent,
latent proviral infection, and what these mechanisms tell us about potential approaches towards
eradication of HIV infection.
Introduction
With more than 7,000 new infections each day, the human immunodeficiency virus (HIV)
pandemic remains a concern of utmost public health importance [1]. Although access to
antiretroviral therapy (ART) is increasing, currently more people are infected every day than
initiate ART. Further, despite highly effective antiretrovirals capable of reducing plasma
viremia to less than 50 copies of HIV per milliliter (ml) in the millions of treated individuals
[2], there is only a single report of an HIV-infected individual in whom HIV infection might
have been cleared [3]. Virus quickly rebounds upon treatment interruption, thus life-long access
and adherence to antiretrovirals are necessary to control viremia [4]. Over the long term, the
burden of life-long ART in millions of patients across the world may not be sustainable.
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HIV persistence is primarily due to the twin phenomenon of HIV to latently infect long-lived
cells of the immune system and continued virus release from undefined reservoirs. For the past
two decades, the majority of therapeutic research in the field has focused on developing
vaccines and designing antiretrovirals to block specific steps in the virus life cycle. Only of
late has there been a reawakening of interest in strategies to purge the latent reservoir of HIV
with the goals of a drug-free remission of viremia and, ultimately, virus eradication. Recently,
several researchers called for a broad collaboration between governments, institutional donors,
academia, and the pharmaceutical industry to pursue anti-latency research similar to current
initiatives for HIV vaccine research [5]. This review summarizes recent discoveries into the
mechanisms that regulate HIV latency, efforts to define and reach still hidden viral reservoirs,
as well as proposed strategies to eradicate HIV.
Persistent HIV infection
ART has been extremely effective at controlling viral replication in HIV infected individuals.
However, persistent expression of HIV RNA (without evidence of full rounds of replication)
can be detected in HIV-infected patients on durably successful ART by research assays in the
plasma [6–7]. Recent studies have demonstrated that intensifying standard ART with an
additional potent drug such as the non-nucleoside reverse transcriptase inhibitor efavirenz, the
fusion inhibitor enfuvirtide, protease inhibitors lopinavir/ritonavir or atazanavir/ritonavir, or
the HIV integrase inhibitor raltegravir does not reduce residual viremia in patients [8–10].
These studies suggest that eradication of HIV may not be achieved by antiretroviral drugs that
block HIV replication and that additional efforts should be focused on purging the persistent
latent viral reservoirs [Fig. 1].
Early in infection, HIV primarily infects activated CD4+ T cells. Infection of these cells is
almost always productive and quickly leads to cell death. Once ART is initiated, studies of the
kinetics of the decay of viremia illustrate multiple phases of decay. The initial two phases of
decay of viremia has been long assumed to originate first from activated CD4 cells, and then
from long-lived cells such as macrophages. However, in ART that includes an HIV integrase
inhibitor only a single initial phase of decay is observed. This led to the suggestion that the
second, slower phase of decay originates from cells with slow rates of cycling in which the
kinetics of replication progress at slower rates [11].
Regardless, following the initial decay, which occurs over a period of a few months, there is
a slower decay thought to represent depletion of virus in cells with a half-life of approximately
39 weeks. The final phase consists of a stable, low level of plasma viremia of approximately
1 to 5 copies per milliliter, observable in most patients with the use of research assays, for
which there is no measurable rate of decay [6].
Resting memory CD4+ T cells are relatively resistant to HIV infection due to the intrinsic
resting phenotype of the cell, which results in a lower efficiency of entry, reverse transcription,
and integration in these cells [12]. Although the number of latently infected resting CD4+ T
cells is very rare (less than 1 per million cells contain a replication competent integrated
genome), the reservoir is rapidly generated early in infection [13]. Largely, seeding of this
reservoir with virus is thought to occur when an activated CD4+ T cell is infected as it is
transitioning to the resting, memory T cell state. Once the cell has obtained a resting phenotype,
virus replication is further impeded due to multiple blocks to the HIV lifecycle that occur in
resting CD4+ T cells. If HIV has already integrated into the DNA of the T cell, then the virus
could then remain latently infected for the life of the cell. It has recently been proposed that
this population of resting CD4+ memory cells containing latent, replication-competent virus
might be expanded if the infected memory cell can undergo mitosis, a natural homeostatic
process that is thought to preserve immunological memory, and can enter cell cycle without
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inducing viral replication and the destruction of the infected cell [14]. If this is so, then the
stable frequency resting cell infection in patients on prolonged ART must reflect a balance
between the extremely rare entry of a new proviral genome into the resting pool during ART,
the activation of a resting memory cell by an immune stimulus, and the homeostatic
proliferation of infected memory CD4+ cells.
Sequence analysis of HIV proviral DNA in resting CD4+ T cells has not uncovered evidence
of viral evolution in this reservoir in patients who are stably suppressed with antiretroviral
therapy [4,7]. Phylogenetic analyses of proviral DNA from resting CD4+ T cells and plasma
HIV RNA indicate that the persistent, low-level viremia in patients on ART might be released
from some other cell type, as plasma sequences sometimes do not match proviral sequences
from resting CD4+ T cells [15–16]. Nevertheless, patients who are stably suppressed on ART
rarely develop resistance to antiretroviral drugs [17], suggesting that there may not be full
rounds of ongoing viral replication in patients on ART, and that plasma viremia stems solely
from virus that has been released from an unidentified cell or a clonal population of cells.
However, it should be mentioned that studies such as the ones cited above do have limitations,
including only sampling virus from the periphery and the current sensitivity of virus detection
assays (approximately 1 copy per ml [18]). One recent report does find evidence of viral
evolution in such patients [19]. Thus, we are still not able to confidently settle the ongoing
debate about whether there is continued viral replication on ART or if plasma viremia only
represents virus released from stable reservoirs.
Mechanisms of proviral latency
Numerous transcriptional and post-transcriptional blocks to HIV replication in resting CD4+
T cells have been identified [Fig. 2]. A major transcriptional block is the lack or sequestering
of activating transcription factors and co-factors in resting CD4+ T cells. For example, low
levels of NFAT, cytoplasmic localization of NF-κB p50-p65, and the sequestration of the
positive transcription elongation factor (P-TEFb) by HEXIM have been described in detail
[20]. The site of virus integration can also have profound effects upon HIV transcriptional
expression. Although, HIV primarily integrates into genomic regions of euchromatin
characterized by active transcription [21], occasionally the virus may integrate into
heterochromatic regions of limited transcriptional activity. Furthermore, virus that integrates
into euchromatin can be subject to transcriptional interference by up or down stream cellular
promoters [22–23].
Once integrated, HIV is subject to the same epigenetic mechanisms of transcriptional
regulation as host DNA. Certain histone modifying enzymes have been shown to maintain HIV
latency including histone deacetylases (HDACs), which deacetylate lysine residues on histone
tails, creating a more condensed, repressive chromatin environment and removing important
docking signals for activating transcription factors [24]. The histone methyltransferases EZH2
and SUV39h1 have also been reported to regulate HIV latency in cell-line models [25–26]. In
addition to histone modifications, integrated proviral genomes have been shown to be
methylated on cytosine residues of DNA surrounding the virus promoter in regions referred to
as CpG islands [27–28]. Cytosine DNA methylation of promoters is associated with
transcriptional silencing and a general resistance to activating signals.
Post-transcriptional mechanisms regulate HIV latency as well. Resting cells have low
expression of polypyrimidine tract binding protein (PTB), a factor involved in export of HIV
RNA to the cytoplasm. Over expression of PTB in resting CD4+ T cells from HIV infected
patients leads to increased transcription of latent HIV ex vivo [29]. This induction of HIV gene
expression is presumably due to increasing the export and eventual translation of the viral
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proteins Tat and Rev, which are important regulators of HIV RNA transcription and nuclear
export, respectively.
Five cellular microRNAs (miRNAs) enriched in resting CD4+ T cells were demonstrated to
inhibit translation of HIV proteins [30]. Like PTB, these miRNAs prevent nuclear
accumulation of the HIV proteins Tat and Rev, thus inhibiting HIV gene expression and RNA
export. Thus, resting cells provide a particularly unfavorable environment for HIV replication
and this can result in silencing of integrated HIV proviral genomes in this population of cells.
In addition to possessing numerous blocks to replication, resting CD4+ T cells contribute to
the persistence of HIV due to their intrinsic stability and processes of antigen-driven and
homeostatic proliferation. Resting CD4+ T cells include both naïve and memory cell
populations. Naïve CD4+ T cells have not been exposed to antigen and rarely contain integrated
HIV proviral DNA. When a naïve CD4+ T cell comes into contact with its corresponding
antigen, it will become an activated CD4+ T cell and proliferate. These activated CD4+ T cells
are permissive to HIV and quickly die following infection. Some activated CD4+ T cells will
revert to a resting state and become memory CD4+ T cells that are ready to respond should
they encounter the same antigen again. Activated CD4+ T cells that become infected as they
are transitioning to a resting memory phenotype are likely to be the source of latent HIV in
this population of cells [31].
Memory CD4+ T cells can be further divided into various functional subsets based on surface
expression markers and these subsets include central memory (TCM), transitional memory
(TTM), effector memory, and terminally differentiated memory cells, the latter of which do not
persist for long periods of time and do not enter the persistent memory pool. A recent study
that examined the prevalence of HIV proviral DNA within these subpopulations observed that
TCM cells possess the highest rate of latent HIV in patients with high CD4 counts [14]. In
addition to being extremely long-lived cells, this population can propagate the latent reservoir
via antigen-driven proliferation. However, patients with low CD4 counts possess a larger latent
reservoir in TTM cells, which persist through homeostatic proliferation driven by interleukin-7
(IL-7). Thus, multiple mechanisms of immune cell stability and proliferation contribute the
persistence of the latent HIV reservoir in resting memory CD4+ T cells.
Models for evaluating anti-latency therapeutic approaches
Linked to the study of causes of HIV latency is the evaluation of strategies to target virus
eradication. Theoretically, anti-latency strategies would purge the latent reservoir by inducing
transcriptional activation of latent virus. Infected cells could undergo apoptosis following virus
expression, and antiretroviral therapy would prevent infection of new cells. Antiviral immune
responses might also aid in the clearance of infected cells, and prevent the spread of viral
infection. Until recently, latency research has primarily made use of numerous cell-line models
where integrated HIV proviral DNA is transcriptionally silent. However, there have been
advances in developing more clinically relevant systems for anti-latency therapy evaluation.
Outgrowth assays using resting CD4+ T cells harvested from HIV-infected patients on ART
has been a useful too for the evaluation of anti-latency approaches [32–33]. Resting cells are
exposed to potential HIV-inducing compounds and maintained in limiting dilution cultures
over a two and a half week period along with CCR5-expressing, stimulated PBMCs to permit
spread of reactivated latent virus. Virus outgrowth is measured at the end of the culture period
by HIV gag p24 antigen ELISA and the number of infected resting CD4+ T cells represented
in the initial cell pool is calculated using a maximum likelihood analysis.
Resting CD4+ T cell infection also occurs in rhesus macaques infected with simian
immunodeficiency virus (SIV), suggesting that this model system may be one means of
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exploring anti-latency therapies [34]. However, studies of proviral latency mechanisms have
not been performed in this model. Thus, it remains to be determined whether the blocks to SIV
expression in the latent reservoir of macaques are the same as those in the resting CD4+ T cells
of humans. Importantly, humanized mouse models have been established that show promise
as a model for anti-latency research. These models include bone marrow-liver-thymus mice
[35] and humanized (hu-) Rag2−/−γc−/− mice [36]. We recently demonstrated that plasma
viremia can be suppressed below the limit of detection following treatment of HIV-infected
hu-Rag2−/−γc−/− mice with combination antiretroviral therapy [37]. When ART is interrupted,
HIV levels quickly rebound and depletion of CD4+ T cells resumes. These findings give hope
that humanized mouse models may soon be utilized to study HIV latency and investigate
potential HIV eradication strategies.
Approaches to target HIV proviral latency in resting CD4+ T cells
Even though other reservoirs may exist, targeting latent virus in resting CD4+ T cells is an
important step in eradicating HIV. Once this population of infected cells is eliminated it may
permit easier identification and study of other reservoirs. Chemical compounds that target
transcription factors and co-factors that are either limiting or sequestered in resting CD4+ T
cells have been proposed as anti-latency therapeutics (reviewed in [38]). These include drugs
such as prostratin, which induces nuclear accumulation of the activating NF-kB heterodimer
p50-p65 and hexamethylbisacetamide (HMBA), which promotes the release of p-TEFb from
HEXIM leading to transcriptional activation of the HIV promoter (Figure 2). Prostratin has
been shown to induce the expression of HIV in both human cell and animal model systems,
but hurdles in pre-clinical safety and toxicity testing have thus far prevented the approval of
this compound for further testing in humans [39–41].
HDACs associate with the integrated proviral HIV promoter and inhibition of HDAC
enzymatic activity leads to outgrowth of latent virus from resting CD4+ T cells of HIV-infected
patients (reviewed in [42]). More recently we have demonstrated that the class I HDACs 1, 2,
and 3 may be particularly important to maintaining HIV latency (Figure 2). These HDACs
associate with the HIV promoter in cell line models of latency, are expressed in the nuclei of
resting CD4+ T cells, and selective chemical inhibition of HDACs 1, 2, and 3 can induce ex
vivo viral outgrowth from the resting CD4+ T cells of HIV infected individuals better than the
non-selective HDAC inhibitor valproic acid. In contrast, inhibitors selective for certain
members of the class II HDACs, including HDACs 4, 5, 7, and 9, do not induce outgrowth of
latent HIV [33,43].
Histone methyltransferases and DNA methyltransferases have also been shown to contribute
to HIV transcriptional repression in cell line models of latency. In recent studies from two
groups, exposure of latently infected cell lines to the DNA cytosine methylation inhibitor 5-
aza-2’ deoxycytidine (5-aza-dC) led to induction of HIV expression (Figure 2) [27–28].
However these investigators and others, had reported in earlier studies that DNA methylation
was relatively unimportant in LTR regulation. Further, it is clear that not all integrated HIV
genomes are heavily methylated at the promoter in resting CD4+ T cells obtained from patients
[27]. Therefore, additional strategies may need to be employed to purge all latent HIV genomes
in this population of cells. Strategies that target multiple transcriptional blocks, such as
combining inhibitors to both selective class I HDACs and specific histone or DNA
methyltransferases, may provide an even more effective induction of latent HIV [44]. But it
appears that studies in animal models, or even human clinical studies, will be required to
definitively answer these questions.
Alternatively, as HATs and HDACs regulate the recruitment and activity of methyltransferases
[45] it is also possible that sufficiently potent and appropriately targeted HDAC inhibitors may
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be sufficient to induce the expression of latent HIV. Indeed, even in heavily methylated
promoters, the most effective inducing agent was found to be the potent HDAC inhibitor
suberoylanilide hydroxamic acid (SAHA) [27].
Specific cellular miRNAs present a post-transcriptional block to HIV expression in resting
CD4+ T cells. Ex vivo exposure of resting CD4+ T cells from HIV-infected patients to 2’-O-
methyl-oligoribonucleotide antisense inhibitors of these specific miRNAs leads to latent virus
outgrowth without T cell activation (Figure 2) [30]. Thus, anti-miRNA inhibitors are another
potential anti-latency therapeutic. Delivery systems for anti-miRNA inhibitors in humans do
not currently exist. However, development of such delivery systems is an area of active research
[46–49]. Consequently, anti-miRNA inhibitors may be a potential therapeutic in the future.
More research is warranted into the effects of inhibiting these specific miRNAs on the host as
a single miRNA can regulate hundreds of target RNA molecules.
The intrinsic properties of stability and proliferation in memory CD4+ T cells present major
obstacles to the eradication of HIV with current antiretroviral therapies. The latent HIV
reservoir in patients who possess high CD4 T cell counts primarily exists in TCM cells. These
cells can persist for decades and integrated virus can be propagated following stimulation with
antigen. Patients who are treated late following initial HIV infection typically have low CD4
T cell counts and high levels of immune activation. In these patients, latent HIV proviral DNA
is primarily detected in TTM cells [14]. Depletion of CD4+ T cells correlates with plasma IL-7
levels and IL-7 promotes the survival and proliferation of TTM cells. Thus, the process of
homeostatic proliferation is potentially a key mediator of persistent latent HIV in the TTM cells
of patients with low CD4 counts. Anti-IL-7 therapies have been proposed as a potential means
to purge this specific latent reservoir by preventing proliferation of infected TTM cells [14].
Although theoretically HIV expression in infected cells will lead to cell death within 1 to 2
days either by viral lysis or immune surveillance, it has been proposed that the addition of the
glutathione-synthesis inhibitor buthionine sulfoximine (BSO) to HDAC inhibitors could
accelerate the apoptosis of cells that are producing virus [50]. Expression of HIV would
decrease the level of glutathione creating a pro-oxidant cellular environment, stimulating HIV
transcription. The combination of BSO and HDAC inhibitors permitted a more potent induction
of virus expression in latent cell line models at lower concentrations than required when HDAC
inhibitors were used alone. Additionally, increased apoptosis of cells following virus induction
was observed following the combined treatment, presumably due to the inability of infected
cells to increase glutathione levels. These findings suggest one strategy of inducing virus
expression and apoptosis of infected cells, while simultaneously decreasing the concentrations
of HDAC inhibitors required to induce virus expression, thereby decreasing toxicity to
uninfected cells.
Concluding remarks
Chronic, lifelong antiretroviral therapy may be needed for decades into the future to prevent
AIDS in the millions of HIV-infected people, and to control the spread of the HIV pandemic.
Several mechanisms that might contribute to the establishment and maintenance of latent
proviral infection have been described, yet it seems most likely that several populations of cells
that are persistently infected will require unique therapeutic approaches. Several strategies, as
described above, have already emerged from our current understanding of persistent HIV
infection. However, obviously no approach has yet been practical or successful. Developing
the ability to eradicate established HIV infection will require a prolonged scientific
commitment, further discoveries in the basic mechanisms of HIV persistence, the development
of new model systems to test therapeutic approaches, and careful but innovative translational
studies.
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Figure 1. Decay of plasma viremia induced by current antiretroviral therapy (ART)
Initiation of potent ART results in a precipitous decline in measurable plasma viremia. Level
of viremia drop below the level of detection of commonly available clinical assays (ca. 50
copies of HIV-1 RNA/ml) within weeks, but sometimes take up to 6 months to decline below
the limit of detection. This initial phase of decay often occurs in a biphasic pattern, as illustrated
here, but a monophasic decline can be seen with regimens that contain an integrase inhibitor.
After this initial decline, the slope(s) of further declines in levels of plasma viremia appear to
gradually approach zero. Stable production of low levels of viremia are detectable in a minority
of patients with more sensitive research assays (a), and even lower levels may be established
in most patient at levels that cannot even be detected with current research assays (b).
Intermittent viremia (blips) may occur due to stochastic surges in viral production and/or
variation in assay performance near its limit of detection, and may be detected in both patient
populations.
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Figure 2. Strategies to purge the latent reservoir
(a) Class I selective histone deacetylase (HDAC) inhibitors inactivate HDACs 1, 2, and 3 at
the human immunodeficiency virus (HIV) long-terminal repeat promoter (LTR). This allows
unopposed activity of histone acetyltransferases (HAT), recruited to the LTR by transcription
factors (TF), resulting in acetylation of histones at nucleosomes near the site of initiation of
LTR transcription, and HIV expression. (b) Hexamethylene bisacetamide (HMBA) induces
the release of positive transcription elongation factor (P-TEFb) from HMBA-induced protein
1 (HEXIM), leading to phosphorylation of RNA polymerase II (RNAP II) at the LTR and
subsequent processive HIV transcription. (c) Cellular microRNAs (miRNA) in resting CD4+
T cells prevent the translation of HIV mRNA. Inhibition of these miRNAs with antisense
miRNA inhibitors permits translation of the HIV proteins Tat and Rev, which translocate to
the nucleus and facilitate HIV expression. (d) Cytosine residues at the LTR can be methylated
by DNA methyltransferases (DNMT), a phenomenon associated with transcriptional silencing.
The DNA methylation inhibitor 5-aza-2’ deoxycytidine (5-aza-dC) removes the methylation
marks and can stimulate HIV expression. (e) Complexes at the enhancer sites of the LTR, such
as C-promoter binding factor-1 (CBF-1), or the homodimeric p50 form of NF-κB may recruit
HDACs during latency. In resting CD4+ T cells, the activating NF-κB heterodimer p50-p65
is sequestered in the cytoplasm. Prostratin induces the nuclear translocation of p50-p65 and
the recruitment of HATs to the NF-κB binding sites on the LTR, resulting in HIV expression.
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